Program
HBS-301
A development code. Also written as “HBS-301 tablet”, “Pitolisant delayed-release” and “HBS-201”.
Its studies are mostly in Cataplexy · Idiopathic Hypersomnia · Narcolepsy, led by Harmony Biosciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Harmony Biosciences | 42 open or running | phase 3since Mar 21, 2026 | Jun 30, 2025 | Oct 2027phase 3 · NCT07675135 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 30, 2025First study: phase 1 study in NarcolepsyFirst studyNCT07051252 · 46 enrolled · United States
- Mar 21, 2026Phase 3 study in Idiopathic HypersomniaPhase 3 reachedNCT07500090 · 248 planned · United States, Canada
- Jun 22, 2026Phase 3 study in CataplexyNCT07675135 · 258 planned · United States, Belgium, Canada and more
- Sep 30, 2026Phase 1 study in Healthy ParticipantsNCT07860736 · 12 enrolled · United States
Ahead
- Oct 2027Primary completion: phase 3 study in CataplexyNCT07675135
- Oct 2027Primary completion: phase 3 study in Idiopathic HypersomniaNCT07500090
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07860736Healthy Participants · United States | 1 | Completed | Jun 28, 2026 | 12 |
| NCT07675135Cataplexy · United States, Belgium, Canada and more | 3 | Recruiting | Oct 2027 | 258 |
| NCT07500090Idiopathic Hypersomnia · United States, Canada | 3 | Recruiting | Oct 2027 | 248 |
| NCT07051252Narcolepsy · United States | 1 | Completed | Oct 13, 2025 | 46 |
How it is read
Names in the registry
- “HBS-301”, 1 entry
- “HBS-301 tablet”, 1 entry
- “Pitolisant delayed-release”, 1 entry
- “HBS-201”, 1 entry
Codes read as this program: HBS301, HBS201.
Conditions, from the studies’ own filings
- Cataplexy, 1 study
- Idiopathic Hypersomnia, 1 study
- Narcolepsy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.